{
    "clinical_study": {
        "@rank": "127968", 
        "brief_summary": {
            "textblock": "To assess the magnitude and duration of the antiviral activity in plasma and the incidence\n      and time to total suppression of detectable HIV RNA in plasma. To assess the long-term\n      safety and tolerability of this combination therapy and the magnitude and duration of the\n      effect of this therapy over CD4 cell counts."
        }, 
        "brief_title": "A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection", 
        "completion_date": {
            "#text": "March 2000", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  CD4 count > 500 cells/mm3.\n\n          -  No HIV-associated symptoms.\n\n          -  Written, informed consent from parent or legal guardian for patients < 18 years old.\n\n          -  Availability for follow-up for at least 96 weeks.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions and symptoms are excluded:\n\n          -  Presence of a newly diagnosed AIDS-defining opportunistic infection requiring acute\n             therapy at the time of enrollment.\n\n          -  Intractable diarrhea.\n\n          -  Signs and symptoms of bilateral peripheral neuropathy >= Grade 2.\n\n          -  Inability to tolerate oral medication.\n\n          -  Hemophilia, other bleeding disorder, or no accessible tonsillar or lymph node tissue.\n\n        Patients with the following prior conditions are excluded:\n\n        History of acute or chronic pancreatitis. 1. Use of potent neurotoxic drugs is not\n        permitted.\n\n          -  No other anti-HIV therapy allowed.\n\n          -  Nelfinavir should not be administered concurrently with rifampin or rifabutin,\n             terfenadine (Seldane), astemizole (Hismanal), cisapride (Propulsid), triazolam\n             (Halcion), and midazolam (Versed).\n\n             1. Any prior antiretroviral therapy.\n\n          -  Prior vaccination with a candidate HIV therapeutic vaccine.\n\n          -  Previous therapy with agents with significant systemic myelosuppressive, neurotoxic,\n             pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start or\n             the expected need for such therapy at the time of enrollment.\n\n          -  Previous therapy with rifampin or rifabutin, terfenadine (Seldane), astemizole\n             (Hismanal), cisapride (Propulsid), triazolam (Halcion), and midazolam (Versed) within\n             14 days prior to study entry or at any time while on study.\n\n        Active alcohol or substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002176", 
            "org_study_id": "244C", 
            "secondary_id": "AI455-062"
        }, 
        "intervention": [
            {
                "intervention_name": "Hydroxyurea", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nelfinavir mesylate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Stavudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Stavudine", 
                "Nelfinavir", 
                "Hydroxyurea"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Pilot Projects", 
            "Didanosine", 
            "Drug Therapy, Combination", 
            "Stavudine", 
            "Hydroxyurea", 
            "Nelfinavir", 
            "Anti-HIV Agents", 
            "Viral Load"
        ], 
        "lastchanged_date": "April 13, 2011", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94110"
                }, 
                "name": "Univ of California at San Francisco Gen Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection", 
        "overall_official": {
            "affiliation": ".", 
            "last_name": ". ., .", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2000", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002176"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 1997", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2011"
    }, 
    "geocoordinates": {
        "Univ of California at San Francisco Gen Hosp": "37.775 -122.419"
    }
}